Patients were randomly assigned ( 2:1 ) twice-daily 150 mg oral linsitinib or placebo via a web-based , centralised randomisation system and stratified according to previous systemic cytotoxic chemotherapy for adrenocortical carcinoma , Eastern Cooperative Oncology Group performance status , and use of one or more oral antihyperglycaemic therapy at randomisation .